Woxart
Health Science November 18, 2026

Why SAMe Powder Requires Enteric Coating and What That Means for Formulators

Why SAMe Powder Requires Enteric Coating and What That Means for Formulators

SAMe (S-adenosyl-L-methionine) is one of the more demanding ingredients in solid dosage form manufacturing. Unlike most amino acid derivatives and nutritional ingredients that can be blended with standard excipients and compressed into tablets using conventional methods, SAMe requires enteric coating to function as intended. Understanding why this is necessary — and what happens when it’s skipped — clarifies both the formulation challenge and the quality parameters that matter most when evaluating SAMe powder as a raw material.


What happens to SAMe in the stomach

The stomach is a hostile environment for SAMe. Gastric acid — with a pH typically between 1.5 and 3.5 in the fasting state — degrades SAMe through several pathways. The adenosyl moiety is acid-labile: at gastric pH, the glycosidic bond connecting adenosine to the sulfonium sulfur is susceptible to hydrolysis, releasing adenosine and S-methylmethionine as degradation products. The active sulfonium configuration, which gives SAMe its methyl-donating function, is also destabilized under acidic conditions.

The practical consequence is that SAMe delivered in a standard tablet or uncoated capsule loses a significant portion of its activity before it can be absorbed. This defeats the purpose of supplementation and means that the dose on the label doesn’t correspond to the dose that reaches systemic circulation.

Enteric coating solves this by applying a polymer layer to the tablet that resists dissolution at gastric pH but dissolves at the higher pH of the small intestine — typically above pH 5.5 to 6.0. The coated tablet passes through the stomach intact, releases its contents in the small intestine, and allows absorption of active SAMe before significant degradation occurs.

The coating materials used

The most widely used enteric coating polymers for SAMe are cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), methacrylic acid copolymers (the Eudragit L and S series), and polyvinyl acetate phthalate (PVAP). Each has different dissolution pH thresholds and application properties.

Eudragit L 30 D-55 dissolves above approximately pH 5.5, releasing content in the proximal small intestine. Eudragit S 100 dissolves above approximately pH 7.0, targeting release further into the intestine. For SAMe, where rapid release and absorption in the upper small intestine is desirable, L-series polymers are more commonly used.

The coating process typically involves spray coating on a pan coater or fluid bed coater, applying the polymer solution in multiple passes to build up an even coating layer of sufficient thickness to provide acid resistance throughout the anticipated gastric residence time (typically 1–2 hours in the fed state, potentially longer in the fasted state for delayed gastric emptying). Coating weight gain — the percentage increase in tablet weight attributable to the coating — is typically 3–8% for effective enteric protection.

Why this matters for raw material quality

The requirement for enteric coating places specific demands on the SAMe powder that goes into the core tablet before coating.

Particle size distribution affects tablet hardness and friability, which in turn affect coating performance. A tablet that is too soft or too friable generates dust during coating, produces an uneven coating surface, and may not provide the acid resistance required. SAMe powder with consistent, fine particle size characteristics compresses more reliably than coarse or inconsistent material.

The salt form of the SAMe powder matters. SAMe tosylate disulfate (the most common commercial form) and SAMe butanedisulfonate (used in several European pharmaceutical formulations) have different compression characteristics, moisture sensitivity, and compatibility profiles with excipients used in tablet manufacture. Formulators should confirm that the excipient package — binder, lubricant, disintegrant — is compatible with the specific salt form being used.

Moisture content of the powder affects compressibility and stability of the compressed core. SAMe is hygroscopic — it absorbs moisture readily from the ambient environment — and high moisture content in the core tablet creates problems in the coating step, where additional moisture exposure from the aqueous coating suspension can soften tablets and compromise coating adhesion. Formulators working with SAMe powder typically establish strict limits on core tablet moisture and control processing environment humidity.

Testing enteric coating performance

The definitive test of enteric coating efficacy is the dissolution test specified in USP (or the equivalent in other pharmacopeias). The test subjects tablets to simulated gastric fluid (pH 1.2) for a defined period (typically 2 hours), then transfers them to simulated intestinal fluid (pH 6.8 or higher) and measures dissolution.

An enteric-coated SAMe tablet that passes the dissolution test should show less than 10% release after 2 hours in simulated gastric fluid and not less than 75% release within a specified time (typically 45 minutes to 1 hour) after transfer to simulated intestinal fluid.

Finished product stability studies should include dissolution testing over time, as enteric coating performance can degrade during storage — particularly under elevated humidity conditions that soften the polymer layer. A tablet that passes dissolution at time zero may fail at 12 or 24 months if the coating is not stable under the storage conditions specified on the label.

What this means for buying decisions

Formulators evaluating SAMe powder for enteric-coated tablet applications should request compression data from the supplier — tablet hardness and friability at standard compression forces, using a representative excipient package. This data, if available, indicates whether the material has been characterized for tablet manufacturing or exists only as a bulk chemical specification.

The SAMe powder specification relevant to tablet manufacturing goes beyond assay and identity. Particle size distribution (D10, D50, D90), bulk and tapped density, angle of repose (a proxy for flowability), and moisture content on delivery are all parameters that affect tablet quality. Suppliers who have characterized their material at this level have typically worked with tablet manufacturers and understand the application — a differentiator from those who supply only to bulk chemical customers who reformulate to powder blends without compression requirements.

For contract manufacturers taking on SAMe tablet projects, the enteric coating step is the highest-risk unit operation. Establishing the core tablet specification and validating the coating process with the specific SAMe powder lot before committing to production scale saves the cost and rework of discovering coating failures mid-campaign.